Cipla Partners With Novartis Pharma AG To Market Diabetes Drug Galvus In India

Cipla Limited, a pharmaceutical company, has announced that it has signed a perpetual licence agreement with Novartis Pharma AG (Switzerland) to manufacture and market Galvus and Galvus combination brands for the treatment of type 2 diabetes beginning January 1, 2026. Cipla informed that the agreement is subject to the fulfilment of certain prerequisite conditions. "We would continue to market and distribute Galvus-branded products in the interim. This agreement is expected to strengthen Cipla's position in India as one of the leading diabetes players "According to a recent BSE filing by the company.

Galvus is a prominent brand in the oral diabetic medication category and one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space. Type 2 diabetes prevents the body from properly utilising insulin, which can result in high blood sugar levels if not treated. "With reported sales of INR 268 Cr (IQVIA MAT February 2023), Galvus has the potential to significantly contribute to Cipla's portfolio in the diabetes care continuum space," Cipla added. Medicines Patent Pool (MPP) had previously reported that it had signed sublicence agreements with Aurobindo, Cipla, and Viatris - through its subsidiary Mylan - to manufacture generic versions of cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP).

Cipla Limited is a multinational pharmaceutical and biotechnology corporation based in Mumbai, India. Khwaja Abdul Hamied established the company in Mumbai in 1935. The company focuses on respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS drugs. Cipla's 47 manufacturing sites around the world use cutting-edge technology platforms to produce 50+ dosage forms and 1,500+ products for 86 markets.